Financial News

Skye Bioscience marks SBI-100 clinical trial progress with new clinical research organization

--News Direct--

Skye Bioscience CEO Punit Dhillon joined Proactive's Natalie Stoberman to share the latest progress on its SBI-100 Ophthalmic Emulsion (OE) clinical trials.

SBI-100 OE, the company's lead program, is focused on developing a treatment for glaucoma, the world's leading cause of irreversible blindness.

Skye Bioscience is a pharmaceutical company unlocking the potential of cannabinoids through the development of its proprietary cannabinoid derivatives to treat diseases with significant unmet needs.

Contact Details

Proactive Investors US

+1 347-449-0879

na-editorial@proactiveinvestors.com

View source version on newsdirect.com: https://newsdirect.com/news/skye-bioscience-marks-sbi-100-clinical-trial-progress-with-new-clinical-research-organization-243499754

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Feedback